Acasti Pharma Operating Expenses 2014-2024 | GRCE
Acasti Pharma operating expenses from 2014 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.
Acasti Pharma Annual Operating Expenses
(Millions of US $) |
| 2024 |
$13 |
| 2023 |
$52 |
| 2022 |
$16 |
| 2021 |
$17 |
| 2020 |
$24 |
| 2019 |
$34 |
| 2018 |
$15 |
| 2017 |
$8 |
| 2016 |
$7 |
| 2015 |
$8 |
| 2015 |
$ |
| 2014 |
$11 |
| 2014 |
$ |
| 2013 |
$8 |
| 2013 |
$ |
Acasti Pharma Quarterly Operating Expenses
(Millions of US $) |
| 2024-06-30 |
$5 |
| 2024-03-31 |
$3 |
| 2023-12-31 |
$3 |
| 2023-09-30 |
$2 |
| 2023-06-30 |
$4 |
| 2023-03-31 |
$38 |
| 2022-12-31 |
$4 |
| 2022-09-30 |
$5 |
| 2022-06-30 |
$5 |
| 2022-03-31 |
$4 |
| 2021-12-31 |
$4 |
| 2021-09-30 |
$4 |
| 2021-06-30 |
$3 |
| 2021-03-31 |
$2 |
| 2020-12-31 |
$2 |
| 2020-09-30 |
$8 |
| 2020-06-30 |
$4 |
| 2020-03-31 |
$4 |
| 2019-12-31 |
$6 |
| 2019-09-30 |
$6 |
| 2019-06-30 |
$8 |
| 2019-03-31 |
$11 |
| 2018-12-31 |
$8 |
| 2018-09-30 |
$8 |
| 2018-06-30 |
$8 |
| 2018-03-31 |
$6 |
| 2017-12-31 |
$4 |
| 2017-09-30 |
$3 |
| 2017-06-30 |
$2 |
| 2017-02-28 |
$2 |
| 2016-11-30 |
$2 |
| 2016-08-31 |
$2 |
| 2016-05-31 |
$2 |
| 2016-03-31 |
$0 |
| 2016-02-29 |
|
| 2015-12-31 |
$0 |
| 2015-09-30 |
$2 |
| 2015-06-30 |
$2 |
| 2015-03-31 |
|
| 2014-12-31 |
$3 |
| 2014-09-30 |
$3 |
| 2014-06-30 |
$3 |
| 2014-03-31 |
|
| 2014-02-28 |
|
| 2013-12-31 |
$3 |
| 2013-09-30 |
$3 |
| 2013-06-30 |
$2 |
| 2013-03-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-GENERIC DRG |
$0.033B |
$0.000B |
|
Acasti Pharma Inc. is a biopharmaceutical company. It is focused on research, development and commercialization of krill oil based forms of omega-3 phospholipid therapies. CaPre (R), Acasti's only prescription drug candidate, is being developed to help prevent and treat hypertriglyceridemia. ONEMIA (R) is a medical food and currently Acasti's only commercialized product. Acasti Pharma Inc. is headquartered in Laval, Canada.
|
